Your browser doesn't support javascript.
loading
Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP.
Kim, Miso; Shim, Hyo Sup; Kim, Sheehyun; Lee, In Hee; Kim, Jihun; Yoon, Shinkyo; Kim, Hyung-Don; Park, Inkeun; Jeong, Jae Ho; Yoo, Changhoon; Cheon, Jaekyung; Kim, In-Ho; Lee, Jieun; Hong, Sook Hee; Park, Sehhoon; Jung, Hyun Ae; Kim, Jin Won; Kim, Han Jo; Cha, Yongjun; Lim, Sun Min; Kim, Han Sang; Lee, Choong-Kun; Kim, Jee Hung; Chun, Sang Hoon; Yun, Jina; Park, So Yeon; Lee, Hye Seung; Cho, Yong Mee; Nam, Soo Jeong; Na, Kiyong; Yoon, Sun Och; Lee, Ahwon; Jang, Kee-Taek; Yun, Hongseok; Lee, Sungyoung; Kim, Jee Hyun; Kim, Wan-Seop.
Afiliação
  • Kim M; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
  • Shim HS; Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Kim S; Department of Genomic Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
  • Lee IH; Department of Oncology and Hematology, Kyungpook National Chilgok University Hospital, Kyungpook National University School of Medicine, Daegu, Korea.
  • Kim J; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Yoon S; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Kim HD; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Park I; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Jeong JH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Yoo C; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Cheon J; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Kim IH; Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Lee J; Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Hong SH; Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Park S; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Jung HA; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Kim JW; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Kim HJ; Division of Oncology and Hematology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.
  • Cha Y; Division of Medical Oncology, Center for Colorectal Cancer, National Cancer Center, Goyang, Korea.
  • Lim SM; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
  • Kim HS; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
  • Lee CK; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
  • Kim JH; Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Chun SH; Division of Medical Oncology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Yun J; Division of Hematology/Oncology, Department of Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
  • Park SY; Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Lee HS; Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
  • Cho YM; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Nam SJ; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Na K; Department of Pathology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Korea.
  • Yoon SO; Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Lee A; Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Jang KT; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Yun H; Department of Genomic Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
  • Lee S; Department of Genomic Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
  • Kim JH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Kim WS; Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
Cancer Res Treat ; 2023 Nov 29.
Article em En | MEDLINE | ID: mdl-38037319
ABSTRACT
In recent years, next-generation sequencing (NGS)-based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancer Res Treat Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancer Res Treat Ano de publicação: 2023 Tipo de documento: Article